Palvella Secures $200 Million Financing to Expand QTORIN Pipeline Across Rare Skin and Vascular Disorders

Palvella Therapeutics has successfully completed an upsized public offering, raising $200 million in gross proceeds through the sale of 1.6 million shares at $125 per share. Underwriters also retain the right to purchase an additional 240,000 shares within 30 days. The company plans to deploy these funds to accelerate development of its QTORIN platform programs, which target serious rare diseases with limited therapeutic options. The offering is anticipated to close by late February 2026, pending customary closing conditions.

Clinical Wins Propel Pipeline Forward

Palvella is a clinical-stage biopharmaceutical company specializing in rare skin conditions and vascular malformations that currently lack FDA-approved treatment options. Its lead asset, QTORIN 3.9% rapamycin anhydrous gel, represents a promising therapeutic approach utilizing mTOR pathway modulation.

The company recently achieved a significant milestone when its Phase 3 SELVA study met its primary efficacy endpoint for microcystic lymphatic malformations (Micro LM). This positive outcome has expedited regulatory planning, with a New Drug Application (NDA) submission targeted for the second half of 2026. Additionally, QTORIN is being evaluated for cutaneous venous malformations—a chronic vascular condition without currently approved therapies.

Angiokeratoma Studies and Expanding Indications

Beyond lymphatic malformations, Palvella is advancing QTORIN into the treatment of clinically significant angiokeratomas. The company expects to initiate a Phase 2 clinical study for this indication in the second half of 2026. This represents a meaningful expansion of the QTORIN platform’s scope in addressing rare vascular skin disorders.

The angiokeratoma program complements Palvella’s broader pipeline strategy, which emphasizes leveraging the QTORIN platform across multiple disease areas. The company’s multi-indication approach demonstrates the potential versatility of its lead therapeutic candidate.

Aggressive Development Timeline for 2026

Palvella has outlined an ambitious series of clinical milestones for the coming months. The company plans to initiate a Phase 2 study for QTORIN pitavastatin in disseminated superficial actinic porokeratosis (DSAP) in the second half of 2026. Concurrently, the Phase 2 angiokeratoma trial will move forward as scheduled.

Looking ahead, Palvella anticipates announcing one additional new QTORIN product candidate by mid-2026, further strengthening the platform’s clinical portfolio. The company also expects to identify and disclose a fourth clinical indication for QTORIN rapamycin during the same timeframe. These announcements underscore management’s confidence in the platform’s broad therapeutic potential.

The $200 million capital raise positions Palvella to execute this comprehensive development strategy while maintaining flexibility for partnership and business development opportunities as its clinical programs advance through key regulatory milestones.